Oneness Biotech , Ltd. Overview
Oneness Biotech , Ltd. (4743.TWO) has a ROE of 0.58%, above the Healthcare sector average of -75.59%.
Get informed when a big investor buys or sells
+ Follow0.58%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Oneness Biotech , Ltd.'s return on equity stands at 0.58%. That is above the Healthcare sector average of -75.59%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Oneness Biotech , Ltd. sits higher the Healthcare benchmark (-75.59%) with a ROE of 0.58%. That is roughly 100.8% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 0.58% for Oneness Biotech , Ltd. means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Oneness Biotech , Ltd.'s ROE evolved across reporting periods, while the comparison chart places 4743.TWO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, ROE is commonly used to spot outliers. Oneness Biotech , Ltd.'s reading of 0.58% (sector avg -75.59%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
